# Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A

> **NCT00839254** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 6181 (actual)

## Conditions studied

- Infections, Streptococcal
- Streptococcus Pneumoniae

## Interventions

- **BIOLOGICAL:** Pneumococcal conjugate vaccine Synflorix (GSK1024850A)
- **BIOLOGICAL:** GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine)
- **BIOLOGICAL:** GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine)

## Key facts

- **NCT ID:** NCT00839254
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02-18
- **Primary completion:** 2012-01-31
- **Final completion:** 2012-01-31
- **Target enrollment:** 6181 (ACTUAL)
- **Last updated:** 2020-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00839254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00839254, "Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00839254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*